IO Biotech, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
IOBT Nasdaq 2834 www.iobiotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for IO Biotech, Inc.

IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy? - May 28th, 2025 7:55 am
IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference - May 20th, 2025 6:05 am
IO Biotech price target raised to $14 from $12 at H.C. Wainwright - May 15th, 2025 10:11 am
IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights - May 14th, 2025 6:05 am
IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025 - Apr 26th, 2025 1:05 pm
IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170 - Apr 25th, 2025 11:00 am
We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate - Apr 12th, 2025 8:44 am
IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting - Mar 25th, 2025 2:35 pm
IO Biotech Named Among Fast Company’s World’s Most Innovative Companies of 2025 - Mar 18th, 2025 6:00 am
IO Biotech Reports 2024 Business Highlights - Mar 4th, 2025 2:17 pm
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference - Feb 23rd, 2025 10:07 am
IO Biotech to Present at the 45th Annual Cowen Health Care Conference - Feb 20th, 2025 6:05 am
IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate - Feb 4th, 2025 6:05 am
IO Biotech enrols all subjects in Phase II trial of cancer combination therapy - Jan 10th, 2025 9:10 am
IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer - Jan 9th, 2025 6:05 am
IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank - Dec 20th, 2024 6:05 am
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights - Nov 12th, 2024 5:05 am
IO Biotech Announces Participation in Upcoming Investor Conferences - Nov 11th, 2024 2:05 pm
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study - Nov 7th, 2024 8:00 am
Here's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Situation - Nov 3rd, 2024 6:52 am